Hyperion Therapeutics (HPTX) Adds Daniel G. Welch to its Board of Directors
Tweet Send to a Friend
Up)
Hyperion Therapeutics (Nasdaq: HPTX) has named Daniel G. Welch to its Board of Directors. Mr. Welch currently serves as Chairman, Chief Executive Officer and President of InterMune, Inc. (Nasdaq: ITMN), a public biotechnology company based in Brisbane, California.
Mr. Welch has more than 30 years of experience in the biotechnology and pharmaceutical industries. Prior to InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., from 2002 to 2003.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Mr. Welch has more than 30 years of experience in the biotechnology and pharmaceutical industries. Prior to InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., from 2002 to 2003.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- CalPERS Wants JPMorgan (JPM) CEO, Chairman Role Seperated
- National Financial Partners (NFP) Promotes Douglas Hammond to CEO
- Otter Tail (OTTR) Director Olson Resigns
Create E-mail Alert Related Categories
Management Changes
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
